19 results on '"Padussis, James C."'
Search Results
2. Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume
- Author
-
Blair, Alex B., Krell, Robert W., Ejaz, Aslam, Groot, Vincent P., Gemenetzis, Georgios, Padussis, James C., Falconi, Massimo, Wolfgang, Christopher L., Weiss, Matthew J., Are, Chandrakanth, He, Jin, and Reames, Bradley N.
- Published
- 2021
- Full Text
- View/download PDF
3. Association of gravity drainage and complications following Whipple: an analysis of the ACS-NSQIP targeted database
- Author
-
Hall, Bradley R., Egr, Zachary H., Krell, Robert W., Padussis, James C., Shostrom, Valerie K., Are, Chandrakanth, and Reames, Bradley N.
- Published
- 2021
- Full Text
- View/download PDF
4. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice
- Author
-
Reames, Bradley N., Blair, Alex B., Krell, Robert W., Groot, Vincent P., Gemenetzis, Georgios, Padussis, James C., Thayer, Sarah P., Falconi, Massimo, Wolfgang, Christopher L., Weiss, Matthew J., Are, Chandrakanth, and He, Jin
- Published
- 2019
- Full Text
- View/download PDF
5. Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution
- Author
-
Raymond, Amanda K., Beasley, Georgia M., Broadwater, Gloria, Augustine, Christina K., Padussis, James C., Turley, Ryan, Peterson, Bercedis, Seigler, Hilliard, Pruitt, Scott K., and Tyler, Douglas S.
- Published
- 2011
- Full Text
- View/download PDF
6. Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma
- Author
-
Toshimitsu, Hiroaki, Yoshimoto, Yasunori, Augustine, Christina K., Padussis, James C., Yoo, Jin S., Angelica Selim, M., Pruitt, Scott K., Friedman, Henry S., Ali-Osman, Francis, and Tyler, Douglas S.
- Published
- 2010
- Full Text
- View/download PDF
7. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice.
- Author
-
Reames, Bradley N., Blair, Alex B., Krell, Robert W., Groot, Vincent P., Gemenetzis, Georgios, Padussis, James C., Thayer, Sarah P., Falconi, Massimo, Wolfgang, Christopher L., Weiss, Matthew J., Are, Chandrakanth, and He, Jin
- Abstract
Objective: The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC). Background: Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear. Methods: An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known. Results: A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6–20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (>10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer 2 months, 43% prefer 4 months, and 11% prefer 6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed. Conclusions: In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of ‘‘resectability.’’ [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix.
- Author
-
Copur, Mehmet Sitki, Cushman-Vokoun, Allison M., Padussis, James C., Wedel, Whitney R., Schroeder, Caleb W., Herold, Daniel J., Lintel, Nicholas J., and Horn, Adam J.
- Abstract
Appendiceal mucinous neoplasms are a rare and heterogeneous group of diseases with challenging clinical management decisions. They account for less than 1% of all cancers but their incidence is on the rise. Treatment is based on their stage and histology. Appendiceal neoplasms frequently metastasize inside the abdomen; this leads to tumor cell growth in the abdominal cavity, known as peritoneal carcinomatosis, and buildup of mucinous material, known as pseudomyxoma peritonei. While low-grade, early-stage tumors can be effectively treated with limited surgical resection, patients with low-grade, advanced-stage disease require peritoneal debulking and hyperthermic intraperitoneal chemotherapy. Therapeutic options for high-grade, advanced-stage mucinous tumors of the appendix have not been well established. Debulking surgery with hyperthermic intraperitoneal chemotherapy preceded and/or followed by systemic chemotherapy has been utilized based on some prospective but not randomized data. We present a case of mucinous adenocarcinoma of the appendix treated with neoadjuvant chemotherapy followed by cytoreductive surgery/hyperthermic intraperitoneal chemotherapy and adjuvant chemotherapy. Preoperative chemotherapy provided a favorable histologic response by converting initial mucinous appendiceal adenocarcinoma histology to a high-grade mucinous appendiceal neoplasm. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Association of Passive Drainage and Risk of Complications after Pancreatectomy
- Author
-
Hall, Bradley R., Padussis, James C., Are, Chandrakanth, and Bradley, Reames N.
- Published
- 2019
- Full Text
- View/download PDF
10. Robotic assisted placement of hepatic artery infusion pump is a safe and feasible approach.
- Author
-
Dhir, Mashaal, Zenati, Mazen S., Padussis, James C., Jones, Heather L., Perkins, Samantha, Clifford, Amber K., Steve, Jennifer, Hogg, Melissa E., Choudry, Haroon A., Holtzman, Matthew P., Zeh, Herbert J., Pingpank, James F., Bartlett, David L., and Zureikat, Amer H.
- Published
- 2016
- Full Text
- View/download PDF
11. Targeting N-cadherin Increases Vascular Permeability and Differentially Activates AKT in Melanoma.
- Author
-
Turley, Ryan S., Yoshihiro Tokuhisa, Hiroaki Toshimitsu, Lidsky, Michael E., Padussis, James C., Fontanella, Andrew, Wanleng Deng, Augustine, Christina K., Beasley, Georgia M., Davies, Michael A., Dewhirst, Mark W., and Tyler, Douglas S.
- Published
- 2015
- Full Text
- View/download PDF
12. Feeding jejunostomy during Whipple is associated with increased morbidity.
- Author
-
Padussis, James C., Zani, Sabino, Blazer, Dan G., Tyler, Douglas S., Pappas, Theodore N., and Scarborough, John E.
- Subjects
- *
JEJUNOSTOMY , *PANCREATICODUODENECTOMY , *POSTOPERATIVE care , *HEALTH outcome assessment , *MEDICAL databases , *SURGICAL complications , *MORTALITY - Abstract
Abstract: Background: Placement of a feeding jejunostomy tube (FJ) is often performed during pancreaticoduodenectomy (PD). Few studies, however, have sought to determine whether such placement affects postoperative outcomes after PD. Materials and methods: This is a retrospective analysis of the National Surgical Quality Improvement Program (NSQIP) database to determine the 30-d-postoperative mortality rate, major complication rate, and overall complication rate of jejunostomy tube placement at the time of PD. Univariate and multivariate comparison of postoperative outcomes between patients with and without FJ placement during PD was performed on a total of 4930 patients. Results: Thirty-day-postoperative mortality did not differ between the two groups (4.0% for patients with FJ versus 2.7% without, P = 0.13), whereas overall morbidity (43.3% with FJ versus 34.6% without, P < 0.0001) and serious morbidity (29.5% with FJ versus 22.8% without, P < 0.0001) were significantly higher in patients undergoing FJ placement during PD. The specific complications that occurred more frequently in FJ patients than patients without FJ included deep space surgical site infection, pneumonia, unplanned reintubation, acute renal failure, and sepsis. Conclusion: Although FJ placement during PD is considered to be routine at many institutions, our analysis of data from NSQIP suggest that FJ placement may be associated with increased postoperative morbidity. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
13. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.
- Author
-
Padussis, James C., Steerman, Samuel N., Tyler, Douglas S., and Mosca, Paul J.
- Subjects
- *
PHARMACOKINETICS , *PHARMACOLOGY , *CHEMICAL kinetics , *DRUG therapy , *NEUROENDOCRINE tumors - Abstract
Two forms of regional chemotherapy for the treatment of advanced melanoma or sarcoma of the extremity are isolated limb perfusion (ILP) and the more recently described isolated limb infusion (ILI). Melphalan is the most commonly employed agent in both ILP and ILI, although it is often used in conjunction with other cytotoxic and/or biologic therapies. While ILP and ILI are far more effective for the treatment of extremity disease than is systemic therapy, there is still significant room for improvement in outcomes, from the standpoint of both response rate and toxicity. An understanding of the pharmacokinetics of regional chemotherapy would allow for the prediction of tumor response and toxicity and therefore patient outcomes. In addition, elucidating the mechanisms of drug resistance would lead to opportunities to develop effective chemo-modulators that enhance the effectiveness of ILP and ILI. This paper reviews progress in these two key areas of active investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
14. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.
- Author
-
Cole, Kathryn E., Ly, Quan P., Hollingsworth, Michael A., Cox, Jesse L., Fisher, Kurt W., Padussis, James C., Foster, Jason M., Vargas, Luciano M., and Talmadge, James E.
- Subjects
- *
MYELOID-derived suppressor cells , *CANCER patients , *GASTROINTESTINAL cancer , *TUMOR-infiltrating immune cells , *IMMUNE checkpoint inhibitors , *T cells , *MONONUCLEOSIS - Abstract
• Immune profile of NCT treated is similar to untreated GI cancer patients. • Decrease in checkpoint marker expression on MDSCs in NCT patients. • Increased PD-1 expression on T-cells in the spleen and PB of NCT patients. In recent years, immune therapy, notably immune checkpoint inhibitors (ICI), in conjunction with chemotherapy and surgery has demonstrated therapeutic activity for some tumor types. However, little is known about the optimal combination of immune therapy with standard of care therapies and approaches. In patients with gastrointestinal (GI) cancers, especially pancreatic ductal adenocarcinoma (PDAC), preoperative (neoadjuvant) chemotherapy has increased the number of patients who can undergo surgery and improved their responses. However, most chemotherapy is immunosuppressive, and few studies have examined the impact of neoadjuvant chemotherapy (NCT) on patient immunity and/or the optimal combination of chemotherapy with immune therapy. Furthermore, the majority of chemo/immunotherapy studies focused on immune regulation in cancer patients have focused on postoperative (adjuvant) chemotherapy and are limited to peripheral blood (PB) and occasionally tumor infiltrating lymphocytes (TILs); representing a minority of immune cells in the host. Our previous studies examined the phenotype and frequencies of myeloid and lymphoid cells in the PB and spleens of GI cancer patients, independent of chemotherapy regimen. These results led us to question the impact of NCT on host immunity. We report herein, unique studies examining the splenic and PB phenotypes, frequencies, and numbers of myeloid and lymphoid cell populations in NCT treated GI cancer patients, as compared to treatment naïve cancer patients and patients with benign GI tumors at surgery. Overall, we noted limited immunological differences in patients 6 weeks following NCT (at surgery), as compared to treatment naive patients, supporting rapid immune normalization. We observed that NCT patients had a lower myeloid derived suppressor cells (MDSCs) frequency in the spleen, but not the PB, as compared to treatment naive cancer patients and patients with benign GI tumors. Further, NCT patients had a higher splenic and PB frequency of CD4+ T-cells, and checkpoint protein expression, as compared to untreated, cancer patients and patients with benign GI tumors. Interestingly, in NCT treated cancer patients the frequency of mature (CD45RO+) CD4+ and CD8+ T-cells in the PB and spleens was higher than in treatment naive patients. These differences may also be associated, in part with patient stage, tumor grade, and/or NCT treatment regimen. In summary, the phenotypic profile of leukocytes at the time of surgery, approximately 6 weeks following NCT treatment in GI cancer patients, are similar to treatment naive GI cancer patients (i.e., patients who receive adjuvant therapy); suggesting that NCT may not limit the response to immune intervention and may improve tumor responses due to the lower splenic frequency of MDSCs and higher frequency of mature T-cells. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
- Author
-
Cole, Kathryn E., Ly, Quan P., Hollingsworth, Michael A., Cox, Jesse L., Padussis, James C., Foster, Jason M., Vargas, Luciano M., and Talmadge, James E.
- Subjects
- *
MYELOID-derived suppressor cells , *CLUSTER analysis (Statistics) , *LECTINS , *HLA histocompatibility antigens , *PHENOTYPES , *NITRIC-oxide synthases - Abstract
• Cancer patient spleen a source of immature myeloid cells. • Higher frequency of MDSCs in cancer patient's peripheral blood versus their spleen. • Clustering analysis reveals novel MDSC subsets. • Checkpoint protein expression is higher in peripheral blood versus spleen. Myeloid derived suppressor cells (MDSCs) can be subset into monocytic (M-), granulocytic (G-) or polymorphonuclear (PMN-), and immature (i-) or early MDSCs and have a role in many disease states. In cancer patients, the frequencies of MDSCs can positively correlate with stage, grade, and survival. Most clinical studies into MDSCs have been undertaken with peripheral blood (PB); however, in the present studies, we uniquely examined MDSCs in the spleens and PB from patients with gastrointestinal cancers. In our studies, MDSCs were rigorously subset using the following markers: Lineage (LIN) (CD3, CD19 and CD56), human leukocyte antigen (HLA)-DR, CD11b, CD14, CD15, CD33, CD34, CD45, and CD16. We observed a significantly higher frequency of PMN- and M-MDSCs in the PB of cancer patients as compared to their spleens. Expression of the T -cell suppressive enzymes arginase (ARG1) and inducible nitric oxide synthase (i-NOS) were higher on all MDSC subsets for both cancer patients PB and spleen cells as compared to MDSCs from the PB of normal donors. Similar findings for the activation markers lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), program death ligand 1 (PD-L1) and program cell death protein 1 (PD-1) were observed. Interestingly, the total MDSC cell number exported to clustering analyses was similar between all sample types; however, clustering analyses of these MDSCs, using these markers, uniquely documented novel subsets of PMN-, M- and i-MDSCs. In summary, we report a comparison of splenic MDSC frequency, subtypes, and functionality in cancer patients to their PB by clustering and cytometric analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Comparative phenotypes of peripheral blood and spleen cells from cancer patients.
- Author
-
Cole, Kathryn E., Ly, Quan P., Hollingsworth, Michael A., Cox, Jesse L., Stromnes, Ingunn M., Padussis, James C., Foster, Jason M., Vargas, Luciano M., and Talmadge, James E.
- Subjects
- *
CANCER cells , *CANCER patients , *BLOOD cells , *T cells , *CELLULAR therapy , *PHENOTYPES , *CYTOTOXIC T cells - Abstract
• Phenotypic comparison of cells from the spleens and PB of cancer patients. • Increased frequency of CD8+PD-1+ T-cells in cancer patients' spleens vs. PB. • Cytotoxic CD8+ T-Cells from cancer patients spleens have potential for ACT. Patients with resectable tumor, either in the body or the tail of the pancreas, and cancer patients with a primary tumor adjacent to the splenic vasculature frequently undergo a splenectomy as standard of care during resection. The spleen provides an unutilized source of lymphocytes with potential utility for adoptive cellular therapy (ACT). In this report, spleen and peripheral blood (PB) cells from cancer patients were compared to one another and normal PB by flow cytometry with a focus on CD8+ T-cells, memory phenotype, and their relative expression of checkpoint proteins including program death ligand-1 (PD1). PD1 is both an activation marker for T-cells including antigen (Ag) specific responses, as well as a marker of T-cell exhaustion associated with co-expression of other checkpoint molecules such as lymphocyte activating gene-3 (LAG-3) and T-cell immunoglobulin and mucin domain containing-3 (TIM-3). In summary, the spleen is a rich source of CD8+PD1+ T-cells, with an 8-fold higher frequency compared to the PB. These CD8+ T-cells are predominantly central and transitional memory T-cells with associated effector phenotypes and low expression of TIM-3 and LAG-3 with potential utility for ACT". [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer.
- Author
-
McNeil LR, Blair AB, Krell RW, Zhang C, Ejaz A, Groot VP, Gemenetzis G, Padussis JC, Falconi M, Wolfgang CL, Weiss MJ, Are C, He J, and Reames BN
- Abstract
Background: Recent literature suggests wide variations exist in the international management of locally advanced pancreatic cancer. This study sought to evaluate how geography contributes to variations in management of locally advanced pancreatic cancer., Methods: An electronic survey investigating preferences for the evaluation and management of locally advanced pancreatic cancer was distributed to an international cohort of pancreatic surgeons. Surgeons were classified according to geographic location of practice, and survey responses were compared across locations., Results: A total of 153 eligible responses were received from 4 continents: North and South America (n = 94, 61.4%), Europe (n = 25, 16.3%), and Asia (n = 34, 22.2%). Preferences for the use and duration of neoadjuvant chemotherapy and radiotherapy varied widely. For example, participants in Asia commonly preferred 2 months of neoadjuvant chemotherapy (61.8%), whereas North and South American participants preferred 4 months (52.1%), and responses in Europe were mixed (P = .006). Participants in Asia were less likely to consider isolated liver or lung metastases contraindications to exploration and consequently had a greater propensity to consider exploration in a vignette of oligometastatic disease (56.7% vs North and South America: 25.6%, Europe: 43.5%; P = .007)., Conclusion: In an international survey of pancreatic surgeons, attitudes regarding locally advanced pancreatic cancer and metastatic disease management varied widely across geographic locations. Better evidence is needed to define optimal management of locally advanced pancreatic cancer., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
18. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.
- Author
-
Seshacharyulu P, Halder S, Nimmakayala R, Rachagani S, Chaudhary S, Atri P, Chirravuri-Venkata R, Ouellette MM, Carmicheal J, Gautam SK, Vengoji R, Wang S, Li S, Smith L, Talmon GA, Klute K, Ly Q, Reames BN, Grem JL, Berim L, Padussis JC, Kaur S, Kumar S, Ponnusamy MP, Jain M, Lin C, and Batra SK
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, DNA Damage, Gene Expression Regulation, Neoplastic, Geranyltranstransferase genetics, Geranyltranstransferase metabolism, Humans, Mice, Signal Transduction, Tumor Microenvironment genetics, rac1 GTP-Binding Protein genetics, rac1 GTP-Binding Protein metabolism, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal radiotherapy, Pancreatic Neoplasms genetics, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms radiotherapy
- Abstract
Background: Radiation therapy (RT) has a suboptimal effect in patients with pancreatic ductal adenocarcinoma (PDAC) due to intrinsic and acquired radioresistance (RR). Comprehensive bioinformatics and microarray analysis revealed that cholesterol biosynthesis (CBS) is involved in the RR of PDAC. We now tested the inhibition of the CBS pathway enzyme, farnesyl diphosphate synthase (FDPS), by zoledronic acid (Zol) to enhance radiation and activate immune cells., Methods: We investigated the role of FDPS in PDAC RR using the following methods: in vitro cell-based assay, immunohistochemistry, immunofluorescence, immunoblot, cell-based cholesterol assay, RNA sequencing, tumouroids (KPC-murine and PDAC patient-derived), orthotopic models, and PDAC patient's clinical study., Findings: FDPS overexpression in PDAC tissues and cells (P < 0.01 and P < 0.05) is associated with poor RT response and survival (P = 0.024). CRISPR/Cas9 and pharmacological inhibition (Zol) of FDPS in human and mouse syngeneic PDAC cells in conjunction with RT conferred higher PDAC radiosensitivity in vitro (P < 0.05, P < 0.01, and P < 0.001) and in vivo (P < 0.05). Interestingly, murine (P = 0.01) and human (P = 0.0159) tumouroids treated with Zol+RT showed a significant growth reduction. Mechanistically, RNA-Seq analysis of the PDAC xenografts and patients-PBMCs revealed that Zol exerts radiosensitization by affecting Rac1 and Rho prenylation, thereby modulating DNA damage and radiation response signalling along with improved systemic immune cells activation. An ongoing phase I/II trial (NCT03073785) showed improved failure-free survival (FFS), enhanced immune cell activation, and decreased microenvironment-related genes upon Zol+RT treatment., Interpretation: Our findings suggest that FDPS is a novel radiosensitization target for PDAC therapy. This study also provides a rationale to utilize Zol as a potential radiosensitizer and as an immunomodulator in PDAC and other cancers., Funding: National Institutes of Health (P50, P01, and R01)., Competing Interests: Declaration of interests Dr. Surinder K. Batra is one of the co-founders of Sanguine Diagnostics and Therapeutics, Inc. All other authors disclosed no potential conflicts of interest., (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
19. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.
- Author
-
Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G, Beasley GM, Augustine CK, Dewhirst MW, and Tyler DS
- Subjects
- Animals, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Agents therapeutic use, Bevacizumab, Cell Line, Tumor, Chemotherapy, Cancer, Regional Perfusion, Drug Delivery Systems, Female, Humans, Melphalan therapeutic use, Mice, Mice, Inbred BALB C, Mice, Nude, Oxygen Consumption drug effects, Rats, Rats, Nude, Vascular Endothelial Growth Factor A antagonists & inhibitors, Vascular Endothelial Growth Factor A immunology, Xenograft Model Antitumor Assays, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents administration & dosage, Capillary Permeability drug effects, Melanoma drug therapy, Melphalan administration & dosage
- Abstract
Purpose: To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced extremity melanoma by enhancing delivery and tumor uptake of regionally infused melphalan (LPAM)., Experimental Design: After treatment with systemic bevacizumab or saline, changes in vascular permeability were determined by spectrophotometric analysis of tumors infused with Evan's blue dye. Changes in vascular structure and tumor hemoglobin-oxygen saturation HbO(2) were determined by intravital microscopy and diffuse reflectance spectroscopy, respectively. Rats bearing the low-VEGF secreting DM738 and the high-VEGF secreting DM443 melanoma xenografts underwent isolated limb infusion (ILI) with melphalan (LPAM) or saline via the femoral vessels. The effect of bevacizumab on terminal drug delivery was determined by immunohistochemical analysis of LPAM-DNA adducts in tumor tissues., Results: Single-dose bevacizumab given three days before ILI with LPAM significantly decreased vascular permeability (50.3% in DM443, P < 0.01 and 35% in DM738, P < 0.01) and interstitial fluid pressure (57% in DM443, P < 0.01 and 50% in DM738, P = 0.01). HbO(2) decreased from baseline in mice following treatment with bevacizumab. Systemic bevacizumab significantly enhanced tumor response to ILI with LPAM in two melanoma xenografts, DM443 and DM738, increasing quadrupling time 37% and 113%, respectively (P = 0.03). Immunohistochemical analyses of tumor specimens showed that pretreatment with systemic bevacizumab markedly increased LPAM-DNA adduct formation., Conclusions: Systemic treatment with bevacizumab before regional chemotherapy increases delivery of LPAM to tumor cells and represents a novel way to augment response to regional therapy for advanced extremity melanoma., (©2012 AACR.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.